Nanotherapeutics Secures $30 Million Loan Facility from Hercules Technology Growth Capital

ALACHUA, Fla.--()--Nanotherapeutics, Inc., an integrated biopharmaceutical company with a focus on advanced development and manufacturing, announced today that it has secured a $30 million loan facility from Hercules Technology Growth Capital, Inc. (NYSE:HTGC). The funds from the loan facility will support the Company’s efforts to expand its manufacturing infrastructure.

Nanotherapeutics’ core competencies are in development and cGMP manufacture of pre-clinical and clinical stage biopharmaceutical products. The Company provides a full range of drug development services and intends to further capitalize on its capabilities through partnerships with government and established companies, as well as continuing to fund the development of its internal pipeline.

About Nanotherapeutics, Inc.

Nanotherapeutics, Inc. is a privately held biopharmaceutical company with a major focus on developing a diversified proprietary pipeline of products having both biodefense and medical applications. Products under development include biodefense medical countermeasures, CNS, wound healing, addiction and pain, oncology, anti-infectives, vaccines and orthopedics. The Company has one FDA cleared injectable biologic, NanoFUSE® DBM, used by orthopedic surgeons as bone graft filler. Nanotherapeutics has in-house cGMP manufacturing, formulation, and expertise in pre-clinical and clinical product development as well as clinical trial management to support its products. Established in 1999, the Company employs several proprietary platform technologies to manipulate and enhance the properties of drug candidates. For more information, visit the Company website at www.nanotherapeutics.com.

About Hercules Technology Growth Capital, Inc.

Hercules Technology Growth Capital, Inc. is the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science, and energy & renewable technology industries, at all stages of development. Since inception (December 2003), Hercules has committed more than $4.2 billion to over 270 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing.

Hercules' common stock trades on the New York Stock Exchange under the ticker symbol "HTGC." In addition, Hercules has two outstanding bond issuances of 7.00 percent Senior Notes due 2019—the April 2019 Notes and September 2019 Notes—which trade on the NYSE under the symbols "HTGZ" and "HTGY," respectively.

Contacts

Nanotherapeutics, Inc.
Gary Ascani, 386-462-9663
Vice President of Business Development
gascani@nanotherapeutics.com

Sharing

Contacts

Nanotherapeutics, Inc.
Gary Ascani, 386-462-9663
Vice President of Business Development
gascani@nanotherapeutics.com